Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
Titel:
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
Auteur:
Sandborn, William J Panés, Julian Danese, Silvio Sharafali, Zaineb Hassanali, Azra Jacob-Moffatt, Rhian Eden, Christopher Daperno, Marco Valentine, John F Laharie, David Baía, Carolina Atreya, Raja Panaccione, Remo Rydzewska, Grazyna Aguilar, Humberto Vermeire, Séverine